248 related articles for article (PubMed ID: 17028507)
21. Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung's disease in newborns - a nationwide cohort study.
Nielsen SW; Ljungdalh PM; Nielsen J; Nørgård BM; Qvist N
Orphanet J Rare Dis; 2017 Jun; 12(1):116. PubMed ID: 28633635
[TBL] [Abstract][Full Text] [Related]
22. SSRIs and birth defects.
Burt V; Miller L; Einarson A
Epidemiology; 2007 May; 18(3):410-1; author reply 412-3. PubMed ID: 17435452
[No Abstract] [Full Text] [Related]
23. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.
Bérard A; Ramos E; Rey E; Blais L; St-André M; Oraichi D
Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):18-27. PubMed ID: 17187388
[TBL] [Abstract][Full Text] [Related]
24. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.
Graner S; Svensson T; Beau AB; Damase-Michel C; Engeland A; Furu K; Hviid A; Håberg SE; Mølgaard-Nielsen D; Pasternak B; Kieler H
BMJ; 2017 Feb; 356():j629. PubMed ID: 28246106
[No Abstract] [Full Text] [Related]
25. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.
Bakker MK; Kölling P; van den Berg PB; de Walle HE; de Jong van den Berg LT
Br J Clin Pharmacol; 2008 Apr; 65(4):600-6. PubMed ID: 17953715
[TBL] [Abstract][Full Text] [Related]
26. Risks associated with selective serotonin reuptake inhibitors in pregnancy.
Malm H; Klaukka T; Neuvonen PJ
Obstet Gynecol; 2005 Dec; 106(6):1289-96. PubMed ID: 16319254
[TBL] [Abstract][Full Text] [Related]
27. Exposure to antazoline-naphazoline eye drops during pregnancy and the risk of congenital malformations: a Danish nationwide cohort study.
Thomseth V; Cejvanovic V; Jimenez-Solem E; Poulsen HE; Utheim TP; Andersen JT
Acta Ophthalmol; 2019 Aug; 97(5):505-509. PubMed ID: 30479070
[TBL] [Abstract][Full Text] [Related]
28. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.
Nordeng H; van Gelder MM; Spigset O; Koren G; Einarson A; Eberhard-Gran M
J Clin Psychopharmacol; 2012 Apr; 32(2):186-94. PubMed ID: 22367660
[TBL] [Abstract][Full Text] [Related]
29. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD.
Margulis AV; Abou-Ali A; Strazzeri MM; Ding Y; Kuyateh F; Frimpong EY; Levenson MS; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):942-51. PubMed ID: 23733623
[TBL] [Abstract][Full Text] [Related]
30. Delivery outcome in relation to maternal use of some recently introduced antidepressants.
Lennestål R; Källén B
J Clin Psychopharmacol; 2007 Dec; 27(6):607-13. PubMed ID: 18004128
[TBL] [Abstract][Full Text] [Related]
31. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage.
Andersen JT; Andersen NL; Horwitz H; Poulsen HE; Jimenez-Solem E
Obstet Gynecol; 2014 Oct; 124(4):655-661. PubMed ID: 25198261
[TBL] [Abstract][Full Text] [Related]
32. Selective serotonin reuptake inhibitors and congenital heart anomalies: comparative cohort studies of women treated before and during pregnancy and their children.
Petersen I; Evans SJ; Gilbert R; Marston L; Nazareth I
J Clin Psychiatry; 2016 Jan; 77(1):e36-42. PubMed ID: 26845280
[TBL] [Abstract][Full Text] [Related]
33. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring.
Bay Bjørn AM; Ehrenstein V; Hundborg HH; Nohr EA; Sørensen HT; Nørgaard M
Am J Ther; 2014; 21(2):73-80. PubMed ID: 23011170
[TBL] [Abstract][Full Text] [Related]
34. Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: a meta-analysis of cohort studies.
Zhang TN; Gao SY; Shen ZQ; Li D; Liu CX; Lv HC; Zhang Y; Gong TT; Xu X; Ji C; Wu QJ
Sci Rep; 2017 Feb; 7():43085. PubMed ID: 28220881
[TBL] [Abstract][Full Text] [Related]
35. Exposure to selective noradrenalin reuptake inhibitors during the first trimester of pregnancy and risk of congenital malformations: A meta-analysis of cohort studies.
Lou ZQ; Zhou YY; Zhang X; Jiang HY
Psychiatry Res; 2022 Oct; 316():114756. PubMed ID: 35932572
[TBL] [Abstract][Full Text] [Related]
36. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
Kulin NA; Pastuszak A; Sage SR; Schick-Boschetto B; Spivey G; Feldkamp M; Ormond K; Matsui D; Stein-Schechman AK; Cook L; Brochu J; Rieder M; Koren G
JAMA; 1998 Feb; 279(8):609-10. PubMed ID: 9486756
[TBL] [Abstract][Full Text] [Related]
37. Prenatal Paternal Selective Serotonin Reuptake Inhibitors Use and Risk of ADHD in Offspring.
Yang F; Liang H; Chen J; Miao M; Yuan W; Nørgaard M; Li J
Pediatrics; 2018 Jan; 141(1):. PubMed ID: 29229680
[TBL] [Abstract][Full Text] [Related]
38. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries.
Kieler H; Artama M; Engeland A; Ericsson O; Furu K; Gissler M; Nielsen RB; Nørgaard M; Stephansson O; Valdimarsdottir U; Zoega H; Haglund B
BMJ; 2012 Jan; 344():d8012. PubMed ID: 22240235
[TBL] [Abstract][Full Text] [Related]
39. Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses.
Uguz F
Expert Opin Drug Saf; 2020 Dec; 19(12):1595-1604. PubMed ID: 33001713
[No Abstract] [Full Text] [Related]
40. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study.
Jimenez-Solem E; Andersen JT; Petersen M; Broedbaek K; Jensen JK; Afzal S; Gislason GH; Torp-Pedersen C; Poulsen HE
BMJ Open; 2012; 2(3):. PubMed ID: 22710132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
